Recent Updates
Recently added Catalysts

Bronchodilator

Phase 2

Asthma | Small molecule | Respiratory |Teva Pharmaceutical Industries Limited|Last Updated: Dec 8, 2021

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindUNCONTROLLED
Total Trials1
Total Enrollment -
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00112411Comparison of Two Bronchodilator Inhalers in Pediatric AsthmaticsPHASE2 COMPLETED -Jun 30, 2005Sep 30, 2005Dec 8, 20219 United States
Unlock Drug Trial Details
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelCROSSOVER
PurposeTREATMENT
Interventions
NameTypeDescription
BronchodilatorDRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range4 Years — 11 Years
SexALL
Healthy VolunteersNo
Study Sites9

Inclusion Criteria: * Persistent asthma for a minimum of six months duration that has been stable for at least four weeks * Predicted FEV1 60-90% * Demonstration of 12% airway reversibility Exclusion Criteria: * Continuous requirement for beta-blockers, monoamine oxidase (MAO) inhibitors, tricycl...

Countries:United States
Unlock Eligibility Criteria